Evidence map›Paper›PMID 40333415›Full record

ReviewAnnual review of genomics and human genetics2025

The Hallmarks of Aneuploidy in Cancer and Congenital Syndromes.

Pan Cheng, Karan Singh, Roger H Reeves, Teresa Davoli

Abstract readReview
In one paragraph

Review in Annual review of genomics and human genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. PARP1 Suppression Drives ROS Resistance in Aneuploid Cancer Cells.bioRxiv : the preprint server for biology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Pan ChengInstitute for Systems Genetics and Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY, USA; email: teresa.davoli@nyulangone.org.
Karan SinghInstitute for Systems Genetics and Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY, USA; email: teresa.davoli@nyulangone.org.
Roger H ReevesDepartment of Physiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Teresa DavoliInstitute for Systems Genetics and Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY, USA; email: teresa.davoli@nyulangone.org.

Funding

Why do Down Syndrome patients have high risk of Hirschsprung disease?R01DK135089 · NIDDK · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ARAVINDA CHAKRAVARTI, Sumantra Chatterjee · 2022 to 2026
$4.2M
MutSensor System: A Set of Highly Sensitive Mutation Reporters to Dissect Genome Stability in Health and DiseaseR01HG012590 · NHGRI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Jef D BOEKE, Teresa Davoli · 2023 to 2026
$3.1M
Deconstructing and targeting aneuploidy in human cancer - Resubmission - 1R37CA248631 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Teresa Davoli · 2021 to 2026
$2.9M
NCI NIH HHS R37 CA248631NHGRI NIH HHS R01 HG012590NIDDK NIH HHS R01 DK135089
6 · The paper itself

Abstract

Aneuploidy, characterized by the gain or loss of chromosomes, plays a critical role in both cancer and congenital aneuploidy syndromes. For any aneuploidy, we can distinguish between its general effects and its chromosome-specific effects. General effects refer to the common cellular stresses induced by aneuploidy, such as impaired proliferation, proteotoxic stress, and altered metabolism, which occur regardless of the specific chromosome involved and profoundly impact cellular and organismal functions. These generalized stresses often hinder cell fitness but can also, under certain conditions, contribute to cancer progression. In contrast, chromosome-specific effects arise from the altered dosage of particular genes on the gained or lost chromosome. These effects vary depending on the chromosome involved and can provide specific fitness effects in cancer cells or distinct developmental phenotypes in congenital aneuploidies like Down syndrome. Understanding the interplay between these two levels of effects is crucial for deciphering the outcomes of aneuploidy. This review synthesizes current knowledge and discusses future directions for unraveling the hallmarks of aneuploidy.

Indexed as

AneuploidyCongenital AbnormalitiesNeoplasmsAnimalsDown SyndromeHumansaneuploidycancerchromosomal instabilitycongenital aneuploidyDown syndromehallmarks

Identifiers

PMID40333415
PMCPMC12828776

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.